Market Closed -
Oslo Bors
10:45:00 2024-05-07 EDT
|
5-day change
|
1st Jan Change
|
6.8
NOK
|
+10.57%
|
|
0.00%
|
-43.33%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
884
|
521.9
|
360
|
385
|
Enterprise Value (EV)
1 |
724.4
|
419.9
|
292.3
|
339.7
|
P/E ratio
|
-26.7
x
|
-8.9
x
|
-8.96
x
|
-7.95
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
10,036
x
|
792
x
|
86,354
x
|
EV / Revenue
|
-
|
8,075
x
|
643
x
|
76,207
x
|
EV / EBITDA
|
-21.3
x
|
-7.28
x
|
-7.44
x
|
-7.27
x
|
EV / FCF
|
-45,704,416
x
|
-12,124,588
x
|
-15,114,711
x
|
-11,576,867
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
5.54
x
|
4.94
x
|
5.53
x
|
8.54
x
|
Nbr of stocks (in thousands)
|
29,968
|
29,992
|
29,997
|
32,081
|
Reference price
2 |
29.50
|
17.40
|
12.00
|
12.00
|
Announcement Date
|
21-05-18
|
22-05-30
|
23-04-21
|
24-04-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5.58
|
7.428
|
-
|
0.052
|
0.4545
|
0.004458
|
EBITDA
1 |
-7.499
|
-15.7
|
-33.95
|
-57.66
|
-39.3
|
-46.75
|
EBIT
1 |
-7.625
|
-15.98
|
-34.7
|
-59.11
|
-40.77
|
-48.38
|
Operating Margin
|
-136.65%
|
-215.13%
|
-
|
-113,674.66%
|
-8,971.05%
|
-1,085,224.09%
|
Earnings before Tax (EBT)
1 |
-7.586
|
-14.98
|
-33.09
|
-58.59
|
-40.57
|
-48.38
|
Net income
1 |
-7.586
|
-14.98
|
-33.09
|
-58.59
|
-40.1
|
-48.33
|
Net margin
|
-135.96%
|
-201.7%
|
-
|
-112,673.42%
|
-8,823.56%
|
-1,084,201.23%
|
EPS
2 |
-0.5042
|
-0.4999
|
-1.104
|
-1.954
|
-1.340
|
-1.510
|
Free Cash Flow
|
-
|
-8.871
|
-15.85
|
-34.63
|
-19.34
|
-29.35
|
FCF margin
|
-
|
-119.43%
|
-
|
-66,598.72%
|
-4,254.27%
|
-658,271.62%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-07-13
|
20-07-13
|
21-05-18
|
22-05-30
|
23-04-21
|
24-04-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
59.2
|
45.4
|
160
|
102
|
67.7
|
45.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-8.87
|
-15.8
|
-34.6
|
-19.3
|
-29.3
|
ROE (net income / shareholders' equity)
|
-23.2%
|
-30.2%
|
-32.8%
|
-44.2%
|
-46.9%
|
-87.7%
|
ROA (Net income/ Total Assets)
|
-11.4%
|
-17.4%
|
-19.5%
|
-25.7%
|
-25.5%
|
-42%
|
Assets
1 |
66.27
|
86.25
|
169.6
|
228.3
|
157.5
|
115
|
Book Value Per Share
2 |
3.790
|
1.400
|
5.330
|
3.530
|
2.170
|
1.410
|
Cash Flow per Share
2 |
3.930
|
0.7900
|
4.650
|
2.760
|
2.310
|
1.450
|
Capex
|
-
|
1.4
|
3.96
|
1.63
|
0.25
|
3.09
|
Capex / Sales
|
-
|
18.84%
|
-
|
3,127.86%
|
55.22%
|
69,375.93%
|
Announcement Date
|
20-07-13
|
20-07-13
|
21-05-18
|
22-05-30
|
23-04-21
|
24-04-18
|
|
1st Jan change
|
Capi.
|
---|
| -43.33% | 18.21M | | +21.74% | 46.81B | | -0.97% | 41.37B | | +47.07% | 41.29B | | -3.52% | 28.87B | | +11.12% | 26.06B | | -19.37% | 19.13B | | +31.18% | 12.39B | | -0.04% | 12.08B | | +0.39% | 11.96B |
Other Biotechnology & Medical Research
|